Pfizer covid-19 pharmaceutical concept stock Chengda pharmaceutical, which has just been listed, is proud in the capital market. The share price of closed three “20cm” limit this week.
Time sharing chart of share price trend of Chengda pharmaceutical
Chengda pharmaceutical’s share price soared by nearly 12% this morning. The turnover rate of throughout the day was 60.50% . In just four trading days, the cumulative maximum increase was as high as 80% . As of today’s closing, the total market value of this week has soared by nearly 5 billion yuan .
From the cro sector, Chengda pharmaceutical ranked first in the three-day increase list , and Wuxi Apptec Co.Ltd(603259) and Joinn Laboratories (China) Co.Ltd(603127) ranked second and third respectively.
According to the one-day list data released by Chengda pharmaceutical after hours, the net outflow of funds from longhubang was 17.12 million yuan. specifically, two institutions do t, buying two, buying three, selling two and selling four respectively. China stock market news securities, known as the “retail investor base”, has two business parts in Lhasa, buying four and selling two seats. in addition, there is hot money Citic Securities Company Limited(600030) Shanghai Liyang Road business department is also on the list, ranking buy four and sell one seat, with a net sales of more than 32 million yuan.
Chengda pharmaceutical on February 17
In terms of news, on February 11, Chengda pharmaceutical replied on interactive easy that company was entrusted by Pfizer API factory to customize and develop pharmaceutical intermediates, including pf-07304814 intermediates.
By consulting Pfizer’s website, Pfizer said that pf-07304814 is an intravenous protease inhibitor for covid-19.
In addition, in February 2022, Pfizer terminated the global clinical development plan of pf-07304814. The decision was based on full information, including a careful review of early data and a comprehensive assessment of the candidate’s potential to successfully meet the needs of patients. the administration of pf-07304814 has been stopped in the active-3 study being conducted by the National Institutes of Health (NIH) .
From Pfizer’s fourth quarter and full year performance report in 2021
Analysts believe that no matter how Pfizer develops pf-07304814, Chengda pharmaceutical’s reply on the interactive platform gives the market imagination space .
On February 15, Chengda pharmaceutical announced that the sales revenue of pharmaceutical intermediates customized and developed by for Pfizer accounted for 0.61% of the company’s revenue in 2020. According to the public information, the annual operating revenue of Chengda pharmaceutical in 2020 was 373 million yuan, calculated at the proportion of 0.61%, the sales revenue generated by pf-07304814 in that year was about 2.28 million yuan .
Zheshang Securities Co.Ltd(601878) Sun Jian said in the research report released on January 10, 2022 that Chengda pharmaceutical is one of the major suppliers of pharmaceutical intermediate cdmo + global L-carnitine. the company has established stable cooperative relations with many pharmaceutical enterprises for more than 10 years, and cdmo has formed a more reasonable product echelon.
Shenwan Hongyuan Group Co.Ltd(000166) in the research report released on December 31, 2021, Lin Jin and other analysts said that the net profit attributable to the parent company from 2018 to 2020 was 671.01/5422.39/121174200 yuan respectively, with an annual compound growth rate of 324.95%, showing a rapid growth trend and strong growth.
